India's GLP-1 drug oversight: regulation, policy, and manufacturing.
India’s drug regulator is intensifying its oversight of GLP-1 weight loss drugs amid rising concerns about improper practices. Inspections across 49 entities revealed violations such as unauthorized sales and improper prescriptions, prompting strict regulatory actions.
The regulatory crackdown includes potential license cancellations for non-compliant firms. An advisory has also been issued to prohibit misleading advertisements related to these medications, emphasizing that GLP-1 drugs should only be used under the guidance of qualified medical professionals.
This increased scrutiny follows growing concerns about the misuse and potential risks associated with GLP-1 drugs, which have gained popularity for their weight loss effects. The regulator’s actions aim to ensure patient safety and maintain the integrity of pharmaceutical practices in India.
The move reflects a broader trend of regulatory bodies globally focusing on the safe and appropriate use of weight loss medications, particularly in light of their increasing demand and potential for off-label use.
About the Author
